­
­
­
­

Inventi Impact: Oncology

Articles

  • Inventi:hcc/19198/16
    Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for\nRadioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease
    01-Jan-1970 Research 2016 : April - June
    Robert M Wolfson, Irina Rachinsky, Deric Morrison, Al Driedger, Tamara Spaic, Stan H M Van Uum

    Introduction. Recombinant human thyroid stimulating hormone (rhTSH) is approved for preparation of thyroid remnant ablation\nwith radioactive iodine (RAI) in low risk patients with well differentiated thyroid cancer (DTC).We studied the safety and efficacy\nof rhTSH preparation for RAI treatment of thyroid cancer patients with nodalmetastatic disease. Methods. A retrospective analysis\nwas performed on 108 patients with histopathologically confirmed nodal metastatic DTC, treated with initial RAI between January\n1, 2000, and December 31, 2007. Within this selected group, 31 and 42 patients were prepared for initial and all subsequent RAI\ntreatments by either thyroid hormone withdrawal (THW) or rhTSH protocols and were followed up for at least 3 years. Results. The\nresponse to initial treatment, classified as excellent, acceptable, or incomplete, was not different between the rhTSH group (57%,\n21%, and 21%, resp.) and the THW group (39%, 13%, and 48%, resp.;

    How to Cite this Article
    CC Compliant Citation: Robert M. Wolfson, Irina Rachinsky, Deric\nMorrison, Al Driedger, Tamara Spaic, and Stan H. M. Van Uum,\nâ??Recombinant Human Thyroid Stimulating Hormone versus\nThyroid Hormone Withdrawal for Radioactive Iodine Treatment\nof Differentiated Thyroid Cancer with Nodal Metastatic Disease,â?\nJournal of Oncology, vol. 2016, Article ID 6496750, 6 pages, 2016.\ndoi:10.1155/2016/6496750, http://creativecommons.org/\nlicenses/by/4.0/.
    Download Full Text